未名医药跌停！子公司停产暴露生产乱象，药品安全岂能儿戏

Core Viewpoint - Unimed Pharmaceutical's subsidiary Tianjin Unimed has been suspended from production and sales due to non-compliance with drug production quality management standards, significantly impacting the company's operations and raising concerns about its internal controls and compliance management [1][2]. Group 1: Company Impact - Tianjin Unimed, a key subsidiary, accounted for 60.09% of Unimed Pharmaceutical's revenue in 2024, generating 217 million yuan [1]. - The suspension of production is expected to exacerbate Unimed Pharmaceutical's operational difficulties, with a projected revenue decline of 16.14% to 360 million yuan and a net loss of 137 million yuan in 2024, representing a 58.70% increase in losses [2]. - The company's stock price fell to the daily limit on April 25, reflecting investor concerns about the ongoing situation [2]. Group 2: Regulatory and Compliance Issues - The suspension was triggered by violations of the 2010 revised Drug Production Quality Management Standards, indicating serious quality management issues within the company [1]. - The company has established a special rectification team to address the root causes and develop a corrective action plan, although the timeline for resuming production remains uncertain [2]. - The incident serves as a warning for the entire industry regarding the importance of adhering to drug production quality standards to ensure patient safety [1].